TY - JOUR
T1 - Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection after Penetrating Keratoplasty
T2 - A Randomized Controlled Trial
AU - Hashemian, Mohammad Nasser
AU - Latifi, Golshan
AU - Ghaffari, Reza
AU - Ghassemi, Hamed
AU - Ghanavati, Mehran Zarei
AU - Mohammadi, Seyed Farzad
AU - Yasseri, Mehdi
AU - Fallah Tafti, Mohammad Reza
AU - Tafti, Zahra Fallah
N1 - Publisher Copyright:
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Purpose: To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft. Methods: Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups - group 1: receiving topical tacrolimus 0.05% as adjuvant therapy to corticosteroid treatment and group 2: receiving only corticosteroid treatment. Main outcome measures were rejection reversal, time to rejection reversal, and recurrence of rejection. Results: Thirty-one eyes of 31 patients (17 and 14 eyes in group 1 and 2, respectively) were included in the study. The rejection episode completely resolved in 88.2% of patients in group 1 and 85.7% of patients in group 2 [hazard ratio = 0.60, 95% confidence interval (CI) = 0.28-1.29, P = 0.191]. After adjusting for preoperative factors using the inverse-probability weighting method, the time to resolution of rejection was significantly shorter in group 1 than group 2 (average treatment effect = 16, 95% CI, 3.7-28.7, P = 0.013). The recurrence rate of rejection was significantly higher in group 2 (39.7, 95% CI, 12.8-92.6 per 1000 months of follow-up) than in group 1 (3.6, 95% CI, 0.05-19.9 likewise); risk ratio: 11.1, 95% CI, 1.3-95.0, P = 0.028. Conclusions: Topical tacrolimus 0.05% as an adjunct to steroids can hasten the resolution of endothelial rejection of a PKP graft and potentially decreases the recurrence of rejection. However, it may not improve rejection reversal success.
AB - Purpose: To evaluate the efficacy of topical tacrolimus 0.05% as adjuvant therapy to corticosteroids in the treatment of acute endothelial rejection of a penetrating keratoplasty (PKP) graft. Methods: Patients with the clinical diagnosis of acute endothelial rejection of a PKP graft were randomized into 2 groups - group 1: receiving topical tacrolimus 0.05% as adjuvant therapy to corticosteroid treatment and group 2: receiving only corticosteroid treatment. Main outcome measures were rejection reversal, time to rejection reversal, and recurrence of rejection. Results: Thirty-one eyes of 31 patients (17 and 14 eyes in group 1 and 2, respectively) were included in the study. The rejection episode completely resolved in 88.2% of patients in group 1 and 85.7% of patients in group 2 [hazard ratio = 0.60, 95% confidence interval (CI) = 0.28-1.29, P = 0.191]. After adjusting for preoperative factors using the inverse-probability weighting method, the time to resolution of rejection was significantly shorter in group 1 than group 2 (average treatment effect = 16, 95% CI, 3.7-28.7, P = 0.013). The recurrence rate of rejection was significantly higher in group 2 (39.7, 95% CI, 12.8-92.6 per 1000 months of follow-up) than in group 1 (3.6, 95% CI, 0.05-19.9 likewise); risk ratio: 11.1, 95% CI, 1.3-95.0, P = 0.028. Conclusions: Topical tacrolimus 0.05% as an adjunct to steroids can hasten the resolution of endothelial rejection of a PKP graft and potentially decreases the recurrence of rejection. However, it may not improve rejection reversal success.
KW - graft rejection
KW - penetrating keratoplasty
KW - tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=85045584355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045584355&partnerID=8YFLogxK
U2 - 10.1097/ICO.0000000000001408
DO - 10.1097/ICO.0000000000001408
M3 - Article
C2 - 29215395
AN - SCOPUS:85045584355
SN - 0277-3740
VL - 37
SP - 307
EP - 312
JO - Cornea
JF - Cornea
IS - 3
ER -